Advertisement

Is change in blood pressure a biomarker of pazopanib and sunitinib efficacy in advanced/metastatic renal cell carcinoma?

Published:December 14, 2015DOI:https://doi.org/10.1016/j.ejca.2015.10.006

      Highlights

      • Hypertension is a commonly observed adverse event with angiogenesis inhibitors.
      • We explore hypertension as a predictive marker with pazopanib and sunitinib in renal cell carcinoma.
      • In data from three trials, hypertension was not associated with efficacy outcomes.

      Abstract

      Aim

      Pazopanib, an oral antiangiogenic agent, is associated with improved outcomes in patients with metastatic renal cell carcinoma. In this retrospective analysis, we explore hypertension, an on-target adverse event, as a predictive marker.

      Methods

      Data from the pazopanib arm of the phase III COMPARZ trial (NCT00720941) comprised the test set. Pooled data from phase II (NCT00244764) and III (NCT00334282) pazopanib trials comprised the validation set. Data from the sunitinib arm of COMPARZ were analysed separately. Measures of efficacy were response rate, progression-free survival (PFS), and overall survival (OS). Mean arterial blood pressure (MAP) was the primary metric, and systolic hypertension (S-HTN) and diastolic hypertension (D-HTN) were secondary metrics; 4- and 12-week landmark analyses were performed.

      Results

      Analyses revealed no significant associations at the landmarks between response and MAP. We observed a trend towards improved PFS with S-HTN at week 4 (hazard ratio [HR] = 0.79, P = 0.060) and week 12 (HR = 0.75, P = 0.073) among pazopanib-treated patients in COMPARZ. This trend was not confirmed at week 12 in the validation set or in sunitinib-treated patients. In the test set, there was a trend towards increased OS in patients with S-HTN by week 4 (HR = 0.76, P = 0.062) and with D-HTN by week 4 (HR = 0.71, P = 0.016) but not by week 12. No significant differences in OS were observed in sunitinib-treated patients for S-HTN or D-HTN.

      Conclusion

      Neither hypertension nor any blood pressure elevation above baseline was associated with efficacy outcomes of pazopanib or sunitinib. Accordingly, management of tyrosine kinase inhibitor-induced hypertension is unlikely to compromise outcome.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Hood J.D.
        • Meininger C.J.
        • Ziche M.
        • Granger H.J.
        VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells.
        Am J Physiol. 1998; 274: H1054-H1058
        • Horowitz J.R.
        • Rivard A.
        • van der Zee R.
        • Hariawala M.
        • Sheriff D.D.
        • Esakof D.D.
        • et al.
        Vascular endothelial growth factor/vascular permeability factor produces nitric oxide-dependent hypotension. Evidence for a maintenance role in quiescent adult endothelium.
        Arterioscler Thromb Vasc Biol. 1997; 17: 2793-2800
        • Robinson E.S.
        • Khankin E.V.
        • Choueiri T.K.
        • Dhawan M.S.
        • Rogers M.J.
        • Karumanchi S.A.
        • et al.
        Suppression of the nitric oxide pathway in metastatic renal cell carcinoma patients receiving vascular endothelial growth factor-signaling inhibitors.
        Hypertension. 2010; 56: 1131-1136
        • Wei W.
        • Jin H.
        • Chen Z.W.
        • Zioncheck T.F.
        • Yim A.P.
        • He G.W.
        Vascular endothelial growth factor-induced nitric oxide- and PGI2-dependent relaxation in human internal mammary arteries: a comparative study with KDR and Flt-1 selective mutants.
        J Cardiovasc Pharmacol. 2004; 44: 615-621
        • Yang R.
        • Thomas G.R.
        • Bunting S.
        • Ko A.
        • Ferrara N.
        • Keyt B.
        • et al.
        Effects of vascular endothelial growth factor on hemodynamics and cardiac performance.
        J Cardiovasc Pharmacol. 1996; 27: 838-844
        • Di Lorenzo G.
        • Autorino R.
        • Bruni G.
        • Carteni G.
        • Ricevuto E.
        • Tudini M.
        • et al.
        Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis.
        Ann Oncol. 2009; 20: 1535-1542
        • Ranpura V.
        • Hapani S.
        • Chuang J.
        • Wu S.
        Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials.
        Acta Oncol. 2010; 49: 287-297
        • Wu S.
        • Chen J.J.
        • Kudelka A.
        • Lu J.
        • Zhu X.
        Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis.
        Lancet Oncol. 2008; 9: 117-123
        • Zhu X.
        • Stergiopoulos K.
        • Wu S.
        Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis.
        Acta Oncologica. 2009; 48: 9-17
        • Rini B.I.
        • Cohen D.P.
        • Lu D.R.
        • Chen I.
        • Hariharan S.
        • Gore M.E.
        • et al.
        Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib.
        J Natl Cancer Inst. 2011; 103: 763-773
        • Rini B.I.
        • Schiller J.H.
        • Fruehauf J.P.
        • Cohen E.E.
        • Tarazi J.C.
        • Rosbrook B.
        • et al.
        Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors.
        Clin Cancer Res. 2011; 17: 3841-3849
        • Sternberg C.N.
        • Davis I.D.
        • Mardiak J.
        • Szczylik C.
        • Lee E.
        • Wagstaff J.
        • et al.
        Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial.
        J Clin Oncol. 2010; 28: 1061-1068
        • Hutson T.E.
        • Davis I.D.
        • Machiels J.P.
        • De Souza P.L.
        • Rottey S.
        • Hong B.F.
        • et al.
        Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma.
        J Clin Oncol. 2009; 28: 475-480
        • Motzer R.J.
        • Hutson T.E.
        • Cella D.
        • Reeves J.
        • Hawkins R.
        • Guo J.
        • et al.
        Pazopanib versus sunitinib in metastatic renal-cell carcinoma.
        N Engl J Med. 2013; 369: 722-731
        • Safar M.E.
        • Boudier H.S.
        Vascular development, pulse pressure, and the mechanisms of hypertension.
        Hypertension. 2005; 46: 205-209
        • van den Meiracker A.H.
        • Danser A.H.
        • Sleijfer S.
        • Kappers M.H.
        Re: Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib.
        J Natl Cancer Inst. 2011; 103 (author reply 1558): 1557
        • George S.
        • Reichardt P.
        • Lechner T.
        • Li S.
        • Cohen D.P.
        • Demetri G.D.
        Hypertension as a potential biomarker of efficacy in patients with gastrointestinal stromal tumor treated with sunitinib.
        Ann Oncol. 2012; 23: 3180-3187
        • Motzer R.J.
        • Escudier B.
        • Tomczak P.
        • Hutson T.E.
        • Michaelson M.D.
        • Negrier S.
        • et al.
        Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.
        Lancet Oncol. 2013; 14: 552-562
        • Anderson J.R.
        • Cain K.C.
        • Gelber R.D.
        Analysis of survival by tumor response.
        J Clin Oncol. 1983; 1: 710-719
        • Dafni U.
        Landmark analysis at the 25-year landmark point.
        Circ Cardiovasc Qual Outcomes. 2011; 4: 363-371
        • Rini B.I.
        • Melichar B.
        • Ueda T.
        • Grunwald V.
        • Fishman M.N.
        • Arranz J.A.
        • et al.
        Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial.
        Lancet Oncol. 2013; 14: 1233-1242
        • Maitland M.L.
        • Bakris G.L.
        • Black H.R.
        • Chen H.X.
        • Durand J.B.
        • Elliott W.J.
        • et al.
        Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors.
        J Natl Cancer Inst. 2010; 102: 596-604
        • Duffaud F.
        • Sleijfer S.
        • Litière S.
        • Ray-Coquard I.
        • Le Cesne A.
        • Papai Z.
        • et al.
        Hypertension (HTN) as a biomarker of efficacy in pazopanib-treated patients (pts) with advanced non-adipocytic soft tissue sarcoma (STS).
        Eur J Cancer. 2013; 49 (Abstract 3832)
        • Hurwitz H.I.
        • Douglas P.S.
        • Middleton J.P.
        • Sledge G.W.
        • Johnson D.H.
        • Reardon D.A.
        • et al.
        Analysis of early hypertension and clinical outcome with bevacizumab: results from seven phase III studies.
        Oncologist. 2013; 18: 273-280